共 161 条
[1]
Duma N(2019)Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment Mayo Clin Proc 94 1623-1640
[2]
Santana-Davila R(2022)The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: a simulation study PLoS ONE 17 167-179
[3]
Molina JR(2020)Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer Semin Cancer Biol 61 68123-68130
[4]
Leiter A(2017)Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naive patients with non-small cell lung cancer harboring EGFR mutations Oncotarget 8 2682-2692
[5]
Kong CY(2016)TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response J Cell Biochem 117 556-565
[6]
Gould MK(2016)Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs J Thorac Oncol 11 323-P635
[7]
Harrison PT(2022)Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients? BMC Cancer 22 P625-1669
[8]
Vyse S(2019)Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial Lancet Oncol 20 1655-1919
[9]
Huang PH(2019)Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 20 1905-370
[10]
Tanaka K(2018)Treatment patterns by EGFR mutation status in non-small cell lung cancer patients in the USA: a retrospective database analysis Adv Ther 35 360-99